MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy

Studies suggest that conventional cancer therapies given after immunotherapy (IT) can boost antitumor immunity and possibly improve response rates and progression-free survival. We report two cases of metastatic breast cancer with durable complete responses (CRs) after sequential IT and endocrine therapy. Immune analyses of these long-term disease-free breast cancer patients previously treated with imiquimod (IMQ) suggest in-situ vaccination is achieved by topical application of the TLR-7 agonist directly onto tumors. Furthermore, IT-induced antigen-specific T cells were expanded by subsequent endocrine therapy and correlated with response, persisting > 2 years. Our findings therefore suggest that the induction/boosting of polyfunctional tumor antigen-specific T in response to sequential immune endocrine therapy and detected directly ex-vivo can serve as a peripheral blood biomarker for true clinical benefit.

[1]  D. Petrylak,et al.  Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.

[2]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Schneeweiss,et al.  Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial , 2013, Cancer Immunology, Immunotherapy.

[5]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[6]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[7]  E. Mittendorf,et al.  Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 , 2008, Clinical Cancer Research.

[8]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[9]  E. Lee,et al.  The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma , 2005, Cancer.

[10]  D. Gabrilovich,et al.  INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect , 2010, Expert opinion on biological therapy.

[11]  M. Cheever.  Twelve immunotherapy drugs that could cure cancers. , 2008, Immunological reviews.

[12]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[13]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[14]  Keith L Black,et al.  Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.

[15]  Yixiang Wang,et al.  Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo , 2009, The Journal of Immunology.

[16]  M. Monden,et al.  NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors , 2004, Cancer Research.

[17]  S. Demaria,et al.  Cross-Talk of Breast Cancer Cells with the Immune System , 2011 .

[18]  I. Davis,et al.  Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage , 2006, Clinical Cancer Research.

[19]  M. Pfreundschuh,et al.  Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer , 2006, International journal of cancer.

[20]  A. Simpson,et al.  CT-X antigen expression in human breast cancer , 2009, Proceedings of the National Academy of Sciences.

[21]  M. Gunduz.  Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways , 2011 .

[22]  D. Jäger,et al.  NY‐ESO‐1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T‐cell and CD79a+ plasmacytic/B‐cell infiltration , 2007, International journal of cancer.

[23]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[24]  S. Demaria,et al.  Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer , 2012, Clinical Cancer Research.

[25]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Roden,et al.  Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ , 2014, Clinical Cancer Research.

[27]  W. Gillanders,et al.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer , 2013, Breast Cancer Research and Treatment.

[28]  S. Adams,et al.  Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1 , 2008, The Journal of Immunology.

[29]  Yao-Tseng Chen,et al.  CT7 (MAGE‐C1) antigen expression in normal and neoplastic tissues , 2002, International journal of cancer.

[30]  M. Ladanyi,et al.  Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7 , 2001, International journal of cancer.

[31]  L. O’Driscoll,et al.  Prevalence and prognostic and predictive relevance of PRAME in breast cancer , 2008, Breast Cancer Research and Treatment.

[32]  M. Mazumdar,et al.  Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. , 2007, Cancer immunity.

[33]  V. Kosma,et al.  Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.

[34]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[35]  C. Bokemeyer,et al.  Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming , 2008, Proceedings of the National Academy of Sciences.

[36]  J. Gribben,et al.  Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy , 2005, Clinical Cancer Research.

[37]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Haaland,et al.  Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. , 2007, Journal of immunology.

[39]  K. Hess,et al.  Effect of HER2 status on distant recurrence in early stage breast cancer , 2012, Breast Cancer Research and Treatment.

[40]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Goldhirsch,et al.  Cancer-testis antigen expression in triple-negative breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[43]  L. Terracciano,et al.  Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study , 2001, Virchows Archiv.

[44]  K. Pantel,et al.  MAGE-A gene expression pattern in primary breast cancer. , 2001, Cancer research.

[45]  Yao-Tseng Chen,et al.  Expression of MAGE‐antigens in normal tissues and cancer , 2000, International journal of cancer.

[46]  A. Schneeweiss,et al.  Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study , 2009, Cancer Immunology, Immunotherapy.